Journal
NEUROCRITICAL CARE
Volume 32, Issue 3, Pages 667-671Publisher
HUMANA PRESS INC
DOI: 10.1007/s12028-020-00978-4
Keywords
COVID-19; Encephalitis; Guillain-Barre syndrome; Acute disseminated encephalomyelitis
Categories
Funding
- NINDS NIH HHS [R21 NS113037] Funding Source: Medline
Ask authors/readers for more resources
The magnitude of the COVID-19 pandemic will result in substantial neurological disease, whether through direct infection (rare), para-infectious complications (less rare), or critical illness more generally (common). Here, we raise the importance of stringent diagnosis and data collection regarding neurological complications of COVID-19; we urge caution in the over-diagnosis of neurological disease where it does not exist, but equally strongly encourage the concerted surveillance for such conditions. Additional to the direct neurological complications of COVID-19 infection, neurological patients are at risk of harm from both structural limitations (such as number of intensive care beds), and a hesitancy to treat with certain necessary medications given risk of nosocomial COVID-19 infection. We therefore also outline the specific management of patients with neuroinflammatory diseases in the context of the pandemic. This article describes the implications of COVID-19 on neurological disease and advertises the Neurocritical Care Society's international data collection collaborative that seeks to align data elements.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available